Syndax Pharmaceuticals, Inc. · NASDAQ:SNDX
Syndax Pharmaceuticals — J.P. Morgan 44th Annual Healthcare Conference (January 2026)
23 slides from Syndax Pharmaceuticals's conference presentation, Jan 12, 2026
Slide 1: J.P. Morgan 44th Annual Healthcare Conference
J.P. Morgan 44th Annual Healthcare Conference January 12, 2026
Slide 2: Forward-looking statements disclosure
Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referenci
Slide 3: Syndax is a commercial-stage oncology company with two approved medicines
Syndax is a commercial-stage oncology company with a track record of execution and two approved medicines with multi-billion-dollar opportunities On the road to profitability, Two first- & best-in-class Three FDA approvals with growing revenue, drugs with opportunities + stable expense outlook, for
Slide 4: Revuforj (revumenib)
Revuforj® (revumenib)
Slide 5: Revuforj is FDA-approved for multiple patient subtypes
REVUFORJ IS FDA-APPROVED FOR MULTIPLE PATIENT SUBTYPES First and only menin inhibitor approved in adults & children ≥1 year of age with: R/R acute leukemia with KMT2A translocation R/R AML with NPM1 mutation Revuforj is FDA approved for the treatment of R/R acute leukemia with a KMT2A translocation
Slide 6: Current Revuforj indications unlock $2B+ TAM in R/R acute leukemia
Current Revuforj indications unlock $2B+ TAM in R/R acute leukemia $5B+ TAM across R/R and 1L With the largest addressable U.S. Market Opportunity ($ B) population and anticipated duration of therapy, Revuforj is poised to become the largest targeted AML therapy $2B+ TAM in R/R Addressable AML popul
Slide 7: Revuforj is positioned for long-term success with best-in-class profile and first-mover advantage
Revuforj is positioned for long-term success with a best-in-class profile and first-mover advantage BEST-IN-CLASS FIRST-MOVER PROFILE ADVANTAGE ➢ Unmatched efficacy across multiple ➢ Robust and growing prescriber base with patient subtypes >1 year of commercial product experience ➢ Well-tolerated wi
Slide 8: Strong Revuforj launch underscores exceptional product profile and execution
Strong Revuforj launch underscores exceptional product profile and execution Growth driven by strong patient demand ~$44M ~1,150 ~$125M Preliminary 4Q25 4Q25 total Preliminary full year net revenue* prescriptions (TRx) 2025 net revenue* Continued acceleration ~38% q/q growth ~35% q/q growth in deman
Slide 9: Evolving clinical practice will drive continued Revuforj growth in 2026
Evolving clinical practice will drive continued Revuforj growth in 2026 1 2 3 Movement to earlier Building transplant Growing adoption in lines of Tx and growing rate in KMT2Ar and R/R NPM1m AML combination use usage post-transplant Tx durations Tx durations patient population 9
Slide 10: Syndax is positioned to be first to the 1L with a menin inhibitor
Syndax is positioned to be first to the 1L with a menin inhibitor, building on a long history of ‘firsts’ with Revuforj First to clinically First FDA approved First menin First to receive First to 1L with validate menin menin inhibitor inhibitor added to FDA approval in a menin inhibitor inhibition
Slide 11: Advancing the broadest data generation plan for Revuforj
Advancing the broadest data generation plan to rapidly deliver practice- changing Revuforj evidence and support global registrations in acute leukemia MAINTENANCE & RELAPSED / FRONTLINE MRD RELAPSE REFRACTORY INELIGIBLE FOR IC (‘UNFIT’) ELIGIBLE FOR IC (‘FIT’) AUGMENT-102 BEAT AML SNDX-708 Post-HSCT
Slide 12: Advancing the broadest data generation plan for Revuforj
Advancing the broadest data generation plan to rapidly deliver practice- changing Revuforj evidence and support global registrations in acute leukemia MAINTENANCE & RELAPSED / FRONTLINE MRD RELAPSE REFRACTORY INELIGIBLE FOR IC (‘UNFIT’) ELIGIBLE FOR IC (‘FIT’) AUGMENT-102 BEAT AML SNDX-708 Post-HSCT
Slide 13: Advancing the broadest data generation plan for Revuforj
Advancing the broadest data generation plan to rapidly deliver practice- changing Revuforj evidence and support global registrations in acute leukemia MAINTENANCE & RELAPSED / FRONTLINE MRD RELAPSE REFRACTORY INELIGIBLE FOR IC (‘UNFIT’) ELIGIBLE FOR IC (‘FIT’) AUGMENT-102 BEAT AML SNDX-708 Post-HSCT
Slide 14: Advancing the broadest data generation plan for Revuforj
Advancing the broadest data generation plan to rapidly deliver practice- changing Revuforj evidence and support global registrations in acute leukemia MAINTENANCE & RELAPSED / FRONTLINE MRD RELAPSE REFRACTORY INELIGIBLE FOR IC (‘UNFIT’) ELIGIBLE FOR IC (‘FIT’) AUGMENT-102 BEAT AML SNDX-708 Post-HSCT
Slide 15: Niktimvo (axatilimab-csfr)
Niktimvo (axatilimab-csfr)
Slide 16: Niktimvo is poised to deliver on the promise of CSF-1R inhibition in cGVHD and beyond
Niktimvo is poised to deliver on the promise of CSF-1R inhibition in cGVHD and beyond Novel MoA in cGVHD to address inflammation and fibrosis Trials underway in 1L cGVHD & IPF to further unlock multi- First and only CSF-1R-blocking antibody billion-dollar opportunity FDA approved in ≥3L cGVHD CONFID
Slide 17: Initial Niktimvo indication represents a $2B U.S. market opportunity
Initial Niktimvo indication represents a $2B U.S. market opportunity, with substantial opportunities for label and geographic expansion ~17,000 U.S. cGVHD patients1 $5B+ TAM $2B TAM with initial Niktimvo indication ~6,500 currently treated 3L+ U.S. cGVHD patients Ongoing combo trials could support f
Slide 18: Strong Niktimvo results highlight importance of this novel medicine
Strong Niktimvo results highlight the importance of this novel medicine to patients and Syndax Niktimvo sales annualizing at >$200M $56M $152M within first launch year Preliminary 4Q25 Preliminary full year 2025 net revenue* net revenue* 22% q/q growth Contribution to Syndax expected to materially g
Slide 19: Multiple drivers for continued Niktimvo growth in 2026
Multiple drivers for continued Niktimvo growth in 2026 1 2 3 Rapid adoption in 4L Patients are staying Solid prescriber base with growing usage on therapy with (~90% of U.S. BMT in 3L cGVHD potential for long centers have ordered) treatment durations 19 3L, third line; 4L, fourth line; BMT, bone mar
Slide 20: Robust Niktimvo clinical development plan underway to drive future growth
Robust Niktimvo clinical development plan underway to drive future growth Chronic graft-versus-host disease (cGVHD) RECURRENT/ FRONTLINE REFRACTORY AGAVE-201 Ph 2 trial Phase 2 trial Topline data AXemplify-357 Ph 3 trial Topline data Axa monotherapy Axa + ruxolitinib expected Axa + corticosteroids e
Slide 21: 2026 Priorities and Anticipated Milestones
2026 Priorities and Anticipated Milestones
Slide 22: Proven execution supports continued focus on revenue growth, pipeline development, and data generation
Proven execution supports continued focus on revenue growth, pipeline development, and data generation 2026 Anticipated Milestones 2025 Key Accomplishments Report topline Ph 2 axatilimab data in IPF in 2H26 ✓ Executed two strong product launches Advance global enrollment in pivotal 1L trials of revu
Slide 23: Slide 23
Syndax Pharmaceuticals — J.P. Morgan 44th Annual Healthcare Conference (January 2026) on 6ix